Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM.

J Magn Reson Imaging. 2010 Mar;31(3):538-48. doi: 10.1002/jmri.22068.

2.

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB.

Neurology. 2009 Oct 13;73(15):1200-6. doi: 10.1212/WNL.0b013e3181bc0184.

3.

Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri.

Ellingson BM, Rand SD, Malkin MG, Schmainda KM.

J Neurooncol. 2010 May;97(3):419-23. doi: 10.1007/s11060-009-0018-y. Epub 2009 Oct 8.

4.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J.

Radiology. 2009 Jul;252(1):182-9. doi: 10.1148/radiol.2521081534.

PMID:
19561256
5.

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.

Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF.

Neurology. 2009 Apr 7;72(14):1217-22. doi: 10.1212/01.wnl.0000345668.03039.90.

6.

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL.

Neoplasia. 2009 Feb;11(2):102-25.

7.

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T.

J Neurooncol. 2009 Feb;91(3):329-36. doi: 10.1007/s11060-008-9718-y. Epub 2008 Oct 25.

PMID:
18953493
8.

Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors.

Kinoshita M, Hashimoto N, Goto T, Kagawa N, Kishima H, Izumoto S, Tanaka H, Fujita N, Yoshimine T.

Neuroimage. 2008 Oct 15;43(1):29-35. doi: 10.1016/j.neuroimage.2008.06.041. Epub 2008 Jul 11.

PMID:
18672074
9.

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Hamstra DA, Galbán CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL.

J Clin Oncol. 2008 Jul 10;26(20):3387-94. doi: 10.1200/JCO.2007.15.2363. Epub 2008 Jun 9.

10.

Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T.

Manenti G, Di Roma M, Mancino S, Bartolucci DA, Palmieri G, Mastrangeli R, Miano R, Squillaci E, Simonetti G.

Radiol Med. 2008 Mar;113(2):199-213. doi: 10.1007/s11547-008-0246-9. Epub 2008 Apr 2. English, Italian.

PMID:
18386122
11.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.

PMID:
18316689
12.

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.

Clin Cancer Res. 2007 Feb 15;13(4):1253-9.

13.

Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity.

Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, Makino K, Nakamura H, Ikushima I, Yamura M, Kochi M, Kuratsu JI, Yamashita Y.

AJNR Am J Neuroradiol. 2006 Aug;27(7):1419-25.

14.

The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.

Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD.

Neoplasia. 2006 Apr;8(4):259-67.

15.

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64. Epub 2005 Nov 2.

16.

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD.

Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9. Epub 2005 Apr 1.

17.

Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans.

Ardekani BA, Guckemus S, Bachman A, Hoptman MJ, Wojtaszek M, Nierenberg J.

J Neurosci Methods. 2005 Mar 15;142(1):67-76.

PMID:
15652618
18.

Vanishing contrast enhancement in malignant glioma after corticosteroid treatment.

Zaki HS, Jenkinson MD, Du Plessis DG, Smith T, Rainov NG.

Acta Neurochir (Wien). 2004 Aug;146(8):841-5. Epub 2004 Jun 7.

PMID:
15254806
19.

How often are nonenhancing supratentorial gliomas malignant? A population study.

Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA.

Neurology. 2002 Sep 24;59(6):947-9.

PMID:
12297589
20.

Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging.

Gauvain KM, McKinstry RC, Mukherjee P, Perry A, Neil JJ, Kaufman BA, Hayashi RJ.

AJR Am J Roentgenol. 2001 Aug;177(2):449-54.

PMID:
11461881

Supplemental Content

Support Center